CPEB2-DT

Across TCGA pan-cancer cohorts, CPEB2-DT RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CPEB2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CPEB2-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CPEB2-DT is over-expressed in tumor, although a few such as ESCA and COAD show the opposite, repressed pattern.

LIHC, BRCA, and ESCA are the cancer types where CPEB2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CPEB2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.076	<.001	8	view →
BRCA	All	All	+0.122	.004	6	view →
ESCA	All	All	−0.098	.003	3	view →
LUSC	All	All	+0.052	.001	3	view →
COAD	Female	All	−0.040	.003	3	view →
KIRC	All	All	+0.070	.004	2	view →
READ	All	All	−0.056	.012	2	view →
LUAD	Female	III,IV	−0.046	.026	2	view →
CHOL	All	All	+0.185	.019	1	view →
THCA	All	All	−0.039	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CPEB2-DT–LIHC

Open the LIHC breakdown →